

Docket Number: 037003-0280617

Client Reference: 1997-30-0568D1



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of HANNA et al.

Group Art Unit: 1642

Application No.: 09/853,581

Examiner: Gary B. Nickol

Filed: May 14, 2001

Confirmation No.: 7197

For: SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR
CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance. Payment of the requisite fee under 37 CFR 1.17(p) is enclosed.

Respectfully Submitted,

A handwritten signature in dark ink, appearing to read "T. A. Cawley, Jr.", written over a horizontal line.

Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944
Customer Number: 00909

12/30/2003 HMARZ11 00000088 033975 09853581
01 FC:1806 180.00 DA

Date: December 22, 2003
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/JBM:ntb



| | | |
|-------------------|---------|----------------|
| Atty. Dkt. No. | M# | Client Ref. |
| | 0280617 | 1997-30-0568D1 |

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

| | |
|---------------------------|----------------------|
| Applicant: HANNA et al. | |
| Appln. No.: 09/853,581 | |
| Filing Date: May 14, 2001 | |
| Examiner: Gary B. Nickol | Group Art Unit: 1642 |

Date: December 22, 2003 Page 1 of 1

U.S. PATENT DOCUMENTS

| Examiner's Initials* | Document Number | Date MM/YYYY | Name (Family Name of First Inventor) | Class | Sub Class | Filing Date (if appropriate) |
|-------------------------|--------------------|-----------------|---|-------|--------------|------------------------------------|
| | AR | | | | | |
| | BR | | | | | |
| | CR | | | | | |
| | DR | | | | | |
| | ER | | | | | |
| | FR | | | | | |
| | GR | | | | | |
| | HR | | | | | |
| | IR | | | | | |
| | JR | | | | | |
| | KR | | | | | |

FOREIGN PATENT DOCUMENTS

| | Document Number | Date MM/YYYY | Country | Inventor Name | English Abstract | | Translation Readily Available | |
|--|--------------------|-----------------|---------|---------------|---------------------|----|-------------------------------------|----|
| | | | | | Enclosed | No | Enclose | No |
| | LR | | | | | | | |
| | MR | | | | | | | |
| | NR | | | | | | | |
| | OR | | | | | | | |
| | PR | | | | | | | |
| | QR | | | | | | | |
| | RR | | | | | | | |

| OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.) | | | | | | | | |
|---|---|--|--|--|--|--|--|--|
| SR | Hallinan et al., "Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs," <i>J Med Chem.</i> , 1996, 39:609-613. | | | | | | | |
| TR | Oka et al., "PGE2 receptor subtype EP1 antagonist may inhibit central interleukin-1 β -induced fever in rats," <i>The American Physiological Society</i> , 1998, R1762-1765. | | | | | | | |
| UR | Isaac et al., "Successful treatment of established rat prostate cancer by transforming growth factor-B1 antisense transfected tumor vaccine," <i>J of Urology</i> , 1997, 157:270. | | | | | | | |
| VR | Murphy et al., "Differential effects of growth hormone and prolactin on murine T cell development and function," <i>J Exp Med.</i> , 1993, 178:231-6. | | | | | | | |
| WR | Richards et al., "Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas," <i>Cell Immunol.</i> , 1998, 184:85-91. | | | | | | | |
| XR | | | | | | | | |

Examiner Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.